Table 2.
Pharmacokinetic parameters of naringenin in single-dose studies (n=10 per groups of rats, n=6 per groups of dogs, n=8 per groups of humans, mean ± SD).
Species | Dose (mg kg-1 or mg a) |
The route of adminstration |
t1/2 (h) |
Tmax (h) |
Cmaxb (ng ml-1 or μg ml-1) |
AUC0-t
c (h·ng ml-1 or h μg ml-1) |
AUC0-∞c (h·ng ml-1 or h μg ml-1) |
Vd (L/kg) |
CL (L/h/kg) |
MRT0-t (h) |
MRT0-∞ (h) |
---|---|---|---|---|---|---|---|---|---|---|---|
Rat | |||||||||||
10.5 | p.o. | 2.08 ± 1.30 | 2.50 ± 1.27 | 0.187 ± 0.114 | 0.518 ± 0.207 | 0.541 ± 0.216 | 74.2 ± 64.4 | 25.1 ± 18.1 | 3.84 ± 1.61 | 4.30 ± 1.97 | |
21 | p.o. | 1.93 ± 1.14 | 3.00 ± 1.41 | 0.539 ± 0.487 | 1.68 ± 1.14 | 1.71 ± 1.15 | 57.5 ± 57.0 | 18.4 ± 12.5 | 5.02 ± 2.90 | 5.22 ± 3.02 | |
42 | p.o. | 2.47 ± 1.33 | 3.30 ± 1.34 | 1.08 ± 0.745 | 4.16 ± 3.80 | 4.22 ± 3.78 | 66.6 ± 67.9 | 18.7 ± 16.6 | 5.20 ± 1.45 | 5.55 ± 1.64 | |
168 | p.o. | 2.75 ± 1.04 | 5.70 ± 2.31 | 1.83 ± 0.858 | 11.3 ± 4.24 | 11.5 ± 4.26 | 93.4 ± 121 | 19.6 ± 17.3 | 7.73 ± 2.25 | 8.03 ± 2.25 | |
42 | i.v. | 2.45 ± 1.38 | 0.040 ± 0.021 | 3.98 ± 2.51 | 2.36 ± 1.12 | 2.39 ± 1.11 | 88.3 ± 113 | 23.4 ± 16.0 | 3.36 ± 2.11 | 3.66 ± 2.14 | |
Dog | |||||||||||
3.1 | p.o. | 2.42 ± 1.15 | 5.67 ± 0.816 | 0.033 ± 0.013 | 0.166 ± 0.063 | 0.191 ± 0.064 | 70.0 ± 63.8 | 18.0 ± 6.73 | 6.33 ± 1.41 | 7.67 ± 2.20 | |
12.4 | p.o. | 1.93 ± 0.890 | 6.00 ± 1.79 | 0.082 ± 0.025 | 0.408 ± 0.160 | 0.463 ± 0.197 | 81.4 ± 32.8 | 32.2 ± 16.4 | 6.80 ± 1.53 | 7.57 ± 2.30 | |
49.6 | p.o. | 1.74 ± 0.547 | 6.33 ± 2.34 | 0.204 ± 0.053 | 1.11 ± 0.697 | 1.15 ± 0.678 | 132 ± 74.2 | 51.7 ± 18.8 | 6.97 ± 1.63 | 7.37 ± 1.65 | |
12.4 | i.v. | 1.62 ± 1.32 | 5.25 ± 3.57 | 34.8 ± 13.6 | 0.142 ± 0.094 | 0.158 ± 0.101 | 224 ± 124 | 178 ± 202 | 4.35 ± 2.56 | 5.14 ± 3.34 | |
Human | |||||||||||
40 | p.o. | 1.26 ± 1.06 | 6.86 ± 2.54 | 11.7 ± 12.4 | 21.6 ± 22.9 | 23.9 ± 22.6 | 61.5 ± 38.4 | 41.5 ± 33.1 | 5.25 ± 0.583 | 6.30 ± 4.77 | |
80 | p.o. | 3.17 ± 4.24 | 8.38 ± 4.24 | 12.1 ± 8.52 | 45.2 ± 37.2 | 72.6 ± 87.8 | 174 ± 158 | 75.9 ± 103 | 8.01 ± 4.88 | 14.3 ± 23.3 | |
160 | p.o. | 1.50 ± 0.838 | 9.13 ± 2.59 | 26.2 ± 18.2 | 91.0 ± 70.6 | 97.8 ± 71.5 | 60.6 ± 22.1 | 31.2 ± 16.1 | 9.82 ± 4.20 | 10.1 ± 5.05 | |
160 (high- fat diet) d |
p.o. | 2.63 ± 1.30 | 8.88 ± 3.36 | 23.3 ± 17.7 | 93.6 ± 52.1 | 164 ± 97.4 | 78.4 ± 20.6 | 22.9 ± 5.99 | 9.54 ± 2.64 | 9.56 ± 2.93 | |
320 | p.o. | 2.67 ± 1.54 | 9.00 ± 2.39 | 73.6 ± 45.6 | 409 ± 118 | 452 ± 110 | 47.0 ± 30.6 | 6.00 ± 2.23 | 10.2 ± 2.47 | 11.1 ± 3.27 | |
480 | p.o. | 3.37 ± 3.38 | 13.1 ± 5.17 | 96.8 ± 76.5 | 615 ± 348 | 805 ± 463 | 55.8 ± 47.4 | 6.32 ± 7.94 | 12.0 ± 2.42 | 12.5 ± 3.34 |
The unit was mg kg-1 for rats and dogs, and mg for humans.
The unit was μg ml-1 for rats and dogs, and ng ml-1 for humans.
The unit was h μg ml-1 for rat and dogs, and h ng ml-1 for humans.
Compared to 160 mg group, the acceptable level of significance was established at P < 0.05*.